{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=16", "query": { "intervention": "daratumumab", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 252, "total_pages": 26, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=daratumumab&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T20:08:39.416Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02514668", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-09-01", "completion_date": "2021-12-02", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • San Francisco, California • Detroit, Michigan + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02514668" }, { "nct_id": "NCT01415882", "title": "Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2012-01-31", "completion_date": "2025-04-30", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415882" }, { "nct_id": "NCT05137054", "title": "A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Linvoseltamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Isatuximab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Nirogacestat", "type": "DRUG" }, { "name": "Cevostamab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2022-08-17", "completion_date": "2032-03-24", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 13, "location_summary": "La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05137054" }, { "nct_id": "NCT05392946", "title": "Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2022-08-11", "completion_date": "2028-09-29", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05392946" }, { "nct_id": "NCT06768489", "title": "A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Smoldering Multiple Myeloma", "Immunoglobulin Light-chain Amyloidosis" ], "interventions": [ { "name": "JNJ-79635322", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2024-12-04", "completion_date": "2029-06-29", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 2, "location_summary": "Denver, Colorado • Atlanta, Georgia", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06768489" }, { "nct_id": "NCT04396496", "title": "Treatment of POEMS Syndrome With Daratumumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "POEMS Syndrome" ], "interventions": [ { "name": "Daratumumab Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-09-22", "completion_date": "2023-10-16", "has_results": true, "last_update_posted_date": "2023-11-13", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396496" }, { "nct_id": "NCT01749969", "title": "SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "isatuximab SAR650984", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2013-02-06", "completion_date": "2023-06-20", "has_results": false, "last_update_posted_date": "2023-07-13", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 5, "location_summary": "San Francisco, California • Tampa, Florida • St Louis, Missouri + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01749969" }, { "nct_id": "NCT04610320", "title": "Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Allosensitization", "Heart Transplant Failure and Rejection" ], "interventions": [ { "name": "Daratumumab-SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ronald Witteles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 8, "start_date": "2021-07-01", "completion_date": "2024-01-26", "has_results": false, "last_update_posted_date": "2024-03-25", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04610320" }, { "nct_id": "NCT03837509", "title": "INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "INCB001158", "type": "DRUG" }, { "name": "Daratumumab SC", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-09-25", "completion_date": "2022-04-05", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 14, "location_summary": "Daphne, Alabama • Tucson, Arizona • Denver, Colorado + 11 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837509" }, { "nct_id": "NCT03275285", "title": "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "isatuximab SAR650984", "type": "DRUG" }, { "name": "carfilzomib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2017-10-25", "completion_date": "2025-01-03", "has_results": true, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-30T20:08:39.416Z", "location_count": 2, "location_summary": "San Francisco, California • Spartanburg, South Carolina", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275285" } ] }